A non-functional 5` alk fusion validated at the rna level as a classical eml4-alk that responds well to the novel alk inhibitor ensartinib: a case report

HIGHLIGHTS

• who: Xiaoyan Zhang and Tonghui Ma and Cuiying Zhang from the University of Texas MD Anderson Center, United States have published the Article: A non-functional 5` ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report, in the Journal: (JOURNAL) of 19/Nov/2019
• what: The authors report a case of lung adenosquamous carcinoma that recurred after surgical resection, harboring a novel 50 NOK fusion form, ALK-CYP27C1, which benefited from the ALK inhibitor ensartinib.

SUMMARY

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.